Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
News Editor's pick

EyePoint CEO says DME biology backs DURAVYU after wet AMD misses, at Jefferies London

EyePoint chief executive Dr. Jay Duker MD told the Jefferies Global Healthcare Conference in London that Phase 2 VERONA data and repeat-dosing safety support taking DURAVYU forward in DME alone after both wet AMD Phase 3 trials missed.

Entrance of the Waldorf Hilton hotel in London, with the EyePoint logo on a white card
The Waldorf Hilton on Aldwych, London (file photo), venue of the Jefferies Global Healthcare Conference, where EyePoint's Dr. Jay Duker MD and George Elston spoke on November 16, 2026. Photo: “The Waldorf Hotel, Aldwych” by David Howard, via Wikimedia Commons, CC BY-SA 2.0; resized, EyePoint logo added by Onyx.
Table of Contents

EyePoint used a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 to argue for taking its sustained-release eye insert DURAVYU forward in diabetic macular edema (DME) alone, after two Phase 3 trials in wet age-related macular degeneration (AMD) missed their primary endpoints. President and chief executive officer Dr. Jay Duker MD said the company has now “checked the safety box”.

EyePoint: DME only, for now

Duker said the insert lasts at least six months in almost all patients. Of the LUGANO and LUCIA wet AMD trials, which reported in August and October, Duker said “the primary endpoints in both trials were missed”, adding that the company is closing them to focus on DME.

Why DME is different

“DME is created by damage to the retinal blood vessels that result in their leakage,” Duker said, while wet AMD is the growth of new blood vessels beneath the retina. EyePoint says DURAVYU blocks both VEGF and inflammatory IL-6 pathways.

What VERONA showed

Duker pointed to the Phase 2 VERONA trial in DME, which randomized 27 patients, with 11 eyes in the 2.7 mg arm and six in the aflibercept control arm. EyePoint has reported a 7.1-letter vision gain in the 2.7 mg arm at week 24, and Duker said that by the end of the trial about half of the DURAVYU eyes had no remaining DME against none of the control eyes. EyePoint has reported that 73% of the 2.7 mg arm stayed supplement-free through week 24, against 50% of controls.

On the small size of the trial, Duker said “the OCT results, which show reduction in fluid, mirrored the visual acuity results”, adding: “they went almost as a mirror image”.

Reading across from wet AMD

Duker said almost 450 patients in the wet AMD trials were dosed every six months, and that “the safety looks quite good.” Duker said pooled fluid measurements were only about 10 microns worse than the control, “an insignificant amount”.

EyePoint has reported that more than half of patients in the wet AMD trials were supplement-free through week 56, and that in this group DURAVYU was non-inferior to on-label aflibercept control. If a biomarker could identify those patients in advance and a third trial were run, Duker said, “it would be obviously much more likely to be successful.”

The DME Phase 3 trials

EyePoint’s Phase 3 COMO and CAPRI trials in DME enrolled more than 550 patients in about five months and compare DURAVYU, redosed every six months, with on-label aflibercept. The company expects topline data early in the fourth quarter of 2027.

Duker said there is no futility analysis, warning that from an early look “what you may see may be misleading”. The company has made the criteria for supplemental injections in the DME trials “a little tighter than what it was prior”, Duker said.

The market case

Duker said second-generation anti-VEGF drugs save patients about one injection a year on average, and that doing better than that “I still think leaves a potentially huge market”. “We offer something that those drugs can’t do, which is consistent drug release for six months or longer,” Duker said.

Duker said: “We still think that the potential for a true sustained release in DME only is still great.”

Cash

Chief financial officer George Elston said EyePoint ended September with $118 million of cash. EyePoint has reported a workforce reduction of about 53% following the LUCIA results. EyePoint said on November 12 that its cash, with $10 million raised after the quarter and planned operational adjustments, should fund operations into late in the third quarter of 2027.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company developing treatments for serious retinal diseases, based in Watertown, Massachusetts. DURAVYU combines vorolanib, a tyrosine kinase inhibitor licensed from Equinox Sciences, with EyePoint’s bioerodible Durasert E sustained-delivery technology. DURAVYU is investigational and has not been approved by the FDA.

Onyx has previously reported on 4D Molecular Therapeutics, which is developing a gene therapy for wet AMD and DME, and on last year’s Jefferies conference.


Sources: EyePoint fireside chat, Jefferies Global Healthcare Conference, London, November 16, 2026; EyePoint conference participation announcement (November 6, 2026); EyePoint third quarter 2026 results (November 12, 2026); Healio on the VERONA trial

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments

More News ↗